In-Young Choi1, Phil Lee2, Peter Adany3, Abbey J Hughes4, Scott Belliston5, Douglas R Denney4, Sharon G Lynch5. 1. Hoglund Brain Imaging Center, Department of Neurology, Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA. 2. Hoglund Brain Imaging Center, Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, USA. 4. Department of Psychology, University of Kansas, Lawrence, KS, USA. 5. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract
BACKGROUND: The oxidative stress hypothesis links neurodegeneration in the later, progressive stages of multiple sclerosis (MS) to the loss of a major brain antioxidant, glutathione (GSH). OBJECTIVE: We measured GSH concentrations among major MS subtypes and examined the relationships with other indices of disease status including physical disability and magnetic resonance imaging (MRI) measures. METHODS: GSH mapping was performed on the fronto-parietal region of patients with relapsing-remitting multiple sclerosis (RRMS, n = 21), primary progressive multiple sclerosis (PPMS, n = 20), secondary progressive multiple sclerosis (SPMS, n = 20), and controls ( n = 28) using GSH chemical shift imaging. Between-group comparisons were performed on all variables (GSH, T2-lesion, atrophy, Expanded Disability Status Scale (EDSS)). RESULTS: Patients with MS had substantially lower GSH concentrations than controls, and GSH was lower in progressive MS (PPMS and SPMS) compared with RRMS. GSH concentrations were not significantly different between PPMS and SPMS, or between RRMS and controls. Brain atrophy was significant in both RRMS and progressive MS compared with controls. CONCLUSION: Markedly lower GSH in progressive MS than RRMS indicates more prominent involvement of oxidative stress in the progressive stage of MS than the inflammatory stage. The association between GSH and brain atrophy suggests the important role of oxidative stress contributing to neurodegeneration in progressive MS, as suggested in other neurodegenerative diseases.
BACKGROUND: The oxidative stress hypothesis links neurodegeneration in the later, progressive stages of multiple sclerosis (MS) to the loss of a major brain antioxidant, glutathione (GSH). OBJECTIVE: We measured GSH concentrations among major MS subtypes and examined the relationships with other indices of disease status including physical disability and magnetic resonance imaging (MRI) measures. METHODS:GSH mapping was performed on the fronto-parietal region of patients with relapsing-remitting multiple sclerosis (RRMS, n = 21), primary progressive multiple sclerosis (PPMS, n = 20), secondary progressive multiple sclerosis (SPMS, n = 20), and controls ( n = 28) using GSH chemical shift imaging. Between-group comparisons were performed on all variables (GSH, T2-lesion, atrophy, Expanded Disability Status Scale (EDSS)). RESULTS:Patients with MS had substantially lower GSH concentrations than controls, and GSH was lower in progressive MS (PPMS and SPMS) compared with RRMS. GSH concentrations were not significantly different between PPMS and SPMS, or between RRMS and controls. Brain atrophy was significant in both RRMS and progressive MS compared with controls. CONCLUSION: Markedly lower GSH in progressive MS than RRMS indicates more prominent involvement of oxidative stress in the progressive stage of MS than the inflammatory stage. The association between GSH and brain atrophy suggests the important role of oxidative stress contributing to neurodegeneration in progressive MS, as suggested in other neurodegenerative diseases.
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Martin Samuelsson; Elisabeth Skogh; Kristina Lundberg; Magnus Vrethem; Karin Öllinger Journal: Psychiatry Res Date: 2013-10-07 Impact factor: 3.222
Authors: Inmaculada Tasset; Eduardo Agüera; Fernando Sánchez-López; Montserrat Feijóo; Ana I Giraldo; Antonio H Cruz; Félix Gascón; Isaac Túnez Journal: Clin Biochem Date: 2012-02-04 Impact factor: 3.281
Authors: Gerty Schreibelt; Jack van Horssen; Saskia van Rossum; Christine D Dijkstra; Benjamin Drukarch; Helga E de Vries Journal: Brain Res Rev Date: 2007-07-27
Authors: Loredana La Mantia; Laura Vacchi; Marco Rovaris; Carlo Di Pietrantonj; George Ebers; Sten Fredrikson; Graziella Filippini Journal: J Neurol Neurosurg Psychiatry Date: 2012-09-05 Impact factor: 10.154
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Catarina M Abreu; Ricardo Soares-Dos-Reis; Pedro N Melo; João B Relvas; Joana Guimarães; Maria José Sá; Andrea P Cruz; Inês Mendes Pinto Journal: Front Mol Neurosci Date: 2018-05-16 Impact factor: 5.639